India, May 26 -- BioVie Inc. (BIVI), a clinical-stage biopharmaceutical company, on Tuesday reported complete enrollment in the Phase 2 ADDRESS-LC trial for Bezisterim in treating neurological symptoms of Long COVID.
Long COVID has affected around 15 million people in the U.S. alone, and manifests with neurological symptoms like fatigue, cognitive dysfunction, post-exertion malaise, and sleep disturbances. There are currently no FDA-approved medications for the treatment of the disease.
Bezisterim (NE3107) is an investigational oral drug that crosses the blood-brain-barrier to modulate key pathways in neuroinflammation and is currently being advanced for the treatment of Long COVID, Alzheimer's and Parkinson's disease.
The Phase 2 ADDRES...